Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias
Objective: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the development of motor symptoms, as well as some non-motor changes. Symptomatic treatment of PD…Movement disorders in pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis
Objective: Our aim was to investigate clinical characteristics and evolution of movement disorders (MD) in pediatric anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Background: Movement disorders account for…Determination of glycine transporter 1 levels with [3H]-NFPS binding in hemi-parkinsonian rats with L-DOPA induced dyskinesia
Objective: To determine the distribution of the glycine transporter 1 (GlyT1) in brain areas implicated in parkinsonism and L-3,4-dihydroxyphenylalanine (L-DOPA) induced dyskinesia in the 6-hydroxydopamine…Prevalence of Movement Disorders After Acute Stroke: a Large Prospective Cohort Stroke Study
Objective: To ascertain the prevalence of acute post-stroke movement disorders (PSMD) in a prospective cohort of acute stroke patients. Background: Post-stroke movement disorders can occur…Chronic administration of bitopertin, a GlyT1 inhibitor, in the dyskinetic 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To evaluate if, upon chronic administration, tolerance to the anti-dyskinetic effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin, would develop, in the 6-hydroxydopamine…Oro-bucco-lingual dyskinesia as a side effect of methotrexate therapy
Objective: to demonstrate association between the tardive dyskinesia and methotrexate therapy. Background: Dystonia is found among patients taking methotrexate. However, methotrexate and tardive oro-bucco-lingual dyskinesia…Belly Dance Dyskinesia, a manifestation of B12 deficiency and hyperhomocysteinuria in MTHFR gene mutation. Videographic record of a case.
Objective: We present a case of probable Belly Dance Dyskinesia (BDD) secondary to vitamin B12 deficiency. Background: BDD is a rare movement disorder (considered a…Amantadine Delayed Release/Extended Release Capsules Reduce the Proportion of the Day Spent in “BAD” Time (ON with Troublesome Dyskinesia or OFF): Analysis of Phase 3 Trial Data
Objective: To evaluate the effect of treatment with amantadine delayed release/extended release (AMT DR/ER) vs. placebo on the proportion of the waking day spent in…Natural progression of patients with Parkinson disease on less pulsatile levodopa therapy
Objective: To evaluate the natural progression of Parkinson disease (PD) in patients on less pulsatile levodopa therapy (LPT). Background: Previously we have shown that patients…Levodopa-induced unilateral orofacial dystonia in multiple system atrophy : case report and video presentation
Objective: The study reports a case of lateral orofacial dystonia in a multiple system atrophy (MSA) patient treated with levodopa, and discusses the clinical characteristics…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 40
- Next Page »